ArticleFrontiers in medicine2021
Case Report: Circulating Anti-SARS-CoV-2 Antibodies Do Not Cross-React With Pemphigus or Pemphigoid Autoantigens.
Article in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Association between vaccination and immunobullous disorders: a brief, updated systematic review with focus on COVID-19.Journal of the European Academy of Dermatology and Venereology : JEADV · 2022Pooled it
- Non-COVID-19 Vaccinations and the Induction of Autoantibodies in Pemphigus Diseases: A Review of the Speculative Issue and Our Clinical-Laboratory Experience.Antibodies (Basel, Switzerland) · 2026Review
- Linear IgA bullous dermatosis in a child after the second dose of inactivated COVID-19 vaccine.Postepy dermatologii i alergologii · 2025Article
- New-onset bullous pemphigoid following the fifth dose of the COVID-19 vaccine Pfizer-BioNTech: A case report.SAGE open medical case reports · 2025Article
- Outcomes and risk factors of COVID-19 in patients with bullous pemphigoid: a cross-sectional study.Frontiers in immunology · 2025Article
- The impact of the mRNA COVID-19 vaccine on the Th-like cytokine profile in individuals with no history of COVID-19: insights into autoimmunity targeting heat shock proteins.Frontiers in immunology · 2025Article
- COVID-19 Vaccine: A Potential Risk Factor for Accelerating the Onset of Bullous Pemphigoid.Vaccines · 2024Article
- A Comprehensive Review on the Intricate Interplay between COVID-19 Immunization and the New Onset of Pemphigus Foliaceus.Vaccines · 2024Review
- New Onset and Exacerbation of Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Systematic Review.Vaccines · 2024Review
- Autoimmune bullous disorder flares following severe acute respiratory syndrome coronavirus 2 vaccination: a case series.Journal of medical case reports · 2023Article
- Case Report: The many faces of bullous pemphigoid.Frontiers in immunology · 2023Article
- Response: Commentary: Bullous pemphigoid associated with COVID-19 vaccines: An Italian multicenter study.Frontiers in medicine · 2023Article
- New-onset pemphigus vegetans and pemphigus foliaceus after SARS-CoV-2 vaccination: A report of 2 cases.JAAD case reports · 2022Article
- Bullous pemphigoid after inactivated COVID-19 vaccination: Case report.Dermatologic therapy · 2022Article
- Pseudo-Pemphigoid Gestationis Eruption Following SARS-CoV-2 Vaccination with mRNA Vaccine.Dermatopathology (Basel, Switzerland) · 2022Article
- Development of severe pemphigus vulgaris following ChAdOx1 nCoV-19 vaccination and review of literature.Journal of cosmetic dermatology · 2022Review
- Article
- Exacerbation of Autoimmune Bullous Diseases After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination: Is There Any Association?Frontiers in medicine · 2022Article
- Targeting heat shock proteins 90 and 70: A promising remedy for both autoimmune bullous diseases and COVID-19.Frontiers in immunology · 2022Review
- Commentary: Bullous pemphigoid associated with COVID-19 vaccines: An Italian multicenter study.Frontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is hypothesized that SARS-CoV-2 has the potential to elicit autoimmunity due to molecular mimicry between immunogenic proteins of the virus and human extracellular molecules. While
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.